Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Next Previous
Trial Profile

A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Pfizer; Seagen

Most Recent Events

  • 26 Feb 2025 Planned End Date changed from 31 Oct 2025 to 30 Sep 2025.
  • 22 Aug 2024 Status changed from recruiting to active, no longer recruiting.
  • 30 Apr 2024 Planned number of patients changed from 120 to 40.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top